BRAF and non-small cell lung carcinoma: Concurrent administration of dabrafenib (150 mg, twice daily, orally) and trametinib (2 mg, daily, orally) have been approved by the United States Food and Drug Administration (FDA) for treating BRAF V600E mutation-positive metastatic NSCLC.